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Background: Scale up of antiretroviral therapy (ART) has led to substantial declines in HIV related morbidity and
mortality. However, attrition from ART care remains a major public health concern and has been identified as one
of the key reportable indicators in assessing the success of ART programs. This study describes the incidence and
predictors of attrition among adults initiating ART in a rural HIV clinic in Coastal Kenya.
Methods: A retrospective cohort study design was used. Adults (≥15 years) initiated ART between January 2008
and December 2010 were followed up for two years. Attrition was defined as individuals who were either
reported dead or lost to follow up (LFU, ≥ 180 days late since the last clinic visit). Kaplan Meier survival
probabilities and Weibull baseline hazard regression analyses were used to model the incidence and predictors
of time to attrition.
Results: Of the 928 eligible participants, 308 (33.2% [95% CI, 30.2 – 36.3]) underwent attrition at an incident rate
of 23.1 (95% CI, 20.6 – 25.8)/100 pyo. Attrition at 6 and 12 months was 18.4% (95% CI, 16.0 – 21.1) and 23.2%
(95% CI, 19.9 – 25.3) respectively. Gender (male vs. female, adjusted hazard ratio [95% CI], p-value: 1.5 [1.1 – 2.0],
p = 0.014), age (15 – 24 vs. ≥ 45 years, 2.2 [1.3 – 3.7], p = 0.034) and baseline CD4 T-cell count (100 – 350 cells/uL vs. <100
cells/uL, 0.5 [0.3 – 0.7], p = 0.002) were independent predictors of time to attrition.
Conclusions: A third of individuals initiating ART were either reported dead or LFU during two years of care, with more
than a half of these occurring within six months of treatment initiation. Practical and sustainable biomedical interventions
and psychosocial support systems are warranted to improve ART retention in this setting.
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The number of HIV infected individuals receiving anti-
retroviral therapy (ART) in Africa rose from less than a
million in 2005 to more than 7 million in 2012 [1],
resulting to substantial declines in HIV related morbidity
and mortality [2-4]. However, attrition from ART care
remains a major public health concern [5]. Indeed, the
World Health Organization (WHO) has identified retention* Correspondence: ahassan@kemri-wellcome.org
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assessing the success of ART programs [6].
A systematic review of data from ART programs in
sub-Saharan Africa (sSA) report attrition rates of 23% at
12 months, 25% at 24 months to 30% at 36 months [7],
with most attrition occurring within the first year after
ART initiation. The main components of attrition have
been reported as loss to follow up (LFU, 56% to 59%)
and death (around 40%) [5,7].
Several other studies, including a meta-analysis of data
from Low- and Middle- Income Countries, have reported
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younger age and male gender as independent predictors
of LFU and death in ART programs [8-12].
In Kenya, the prevalence of HIV infection among
adults aged 15–64 years was estimated at 5.6% in 2012
[13], with an estimated 1.6 million individuals living with
HIV infection by the end of 2011 [14]. Kenya is one of
the ten sub-Saharan countries that have achieved more
than 60% treatment coverage [15], with an estimated 72%
coverage by the end of 2011 [14]. The number of HIV-
infected individuals on ART in the country has increased
from an estimated 10,000 in 2003 to more than 400,000 in
2011 [14]. However, as in many other sub-Saharan coun-
tries, attrition remains one of the key challenges to the
success of the national ART program.
A handful of studies have been done to describe attri-
tion in individuals on ART in Kenya. Data from an urban
slum in Nairobi report attrition probabilities of around
17% at 6 months to 35% at 24 months [16]. Follow up data
from the same program report male gender, younger age
and advanced HIV disease as risk factors for ART attrition
[17]. More data looking at ART treatment costs from
three rural outpatient clinics in the Rift Valley province
report 12 months attrition of between 16% and 20% [18].
To continuously evaluate the success of ART programs
in sSA, data on attrition as one of the key WHO report-
able indicators should be periodically reported. To date,
there is a paucity of data to describe attrition from ART
care in Coastal Kenya. This study aimed to contribute to
this pool of data by describing the incidence and predic-
tors of attrition among adults initiating ART in a rural
HIV clinic in Coastal Kenya.
Methods
Study site
The study was carried out at the HIV clinic in Kilifi
District Hospital (KDH), a secondary level public health
facility located in a rural part of Coastal Kenya and with
a catchment population of an estimated 260,000 people
[19]. The clinic began providing HIV services in 2004
and according to the Kenyan National AIDS and STI
Control Program guidelines [20,21].
During the study period, ART eligibility was based on
WHO clinical staging (III or IV, regardless of CD4 T-cell
count) and CD4 T-cell count (<350 cells/ul, regardless
of clinical staging). Individuals meeting the eligibility cri-
teria were taken through ART preparedness and counsel-
ing, started on a standard ART regimen and given an
initial two weeks appointment to assess progress and side
effects. Thereafter, monthly or two monthly follow-up ap-
pointments were given based on adherence and distance
from the clinic. At the time of the study, the clinic did
not have an active defaulter-tracing program, which was
mostly due to resource constraints. Instead, a passivesurveillance approach was used. Patients who did not
return for follow up care were considered LFU. Deaths
were reported by family members, friends and relatives,
and documented as such.
Study design
A retrospective cohort study design was used. HIV-infected
individuals aged ≥15 years initiated ART in the clinic over a
three-year period (between January 2008 and December
2010) were considered eligible. Individuals who initi-
ated ART and were transferred-in from other facilities
were excluded from the analyses. Eligible participants
were followed up for a period of 2 years from the date
of ART initiation.
Sources of data
These have been described elsewhere [22]. In brief, socio-
demographic data including gender, date of birth, marital
status, highest level of education, religion and residence
sub-location were routinely collected at the time of regis-
tration into HIV care on standardized forms by trained
counselors and fieldworkers. Actual distance between in-
dividual’s sub-location and the hospital was estimated in
kilometers (km) using ArcInfo (ArcCatalog v.9.2).
Clinical data including anthropometry, WHO clinical
staging, ART start date, ART regimen and appointment
dates were routinely captured at every clinic visit in real
time on standardized forms by trained clinicians. Pre-ART
duration was defined as the period from registration into
HIV care to ART initiation. Laboratory results, including
CD4 T-cell lymphocyte counts were also captured.
A trained data clerk entered these data into an electronic
data system, which was implemented in 2007. Individuals
initiated ART prior to or in 2007 were hence excluded
from the analysis due to lack of follow up data there from.
Outcome definition
The primary outcome was attrition from ART care. For
the purpose of this study, attrition was defined as individ-
uals on ART care who were either LFU or reported dead
at the end of the 2 years follow-up period.
Various studies have used different definitions of LFU
in the HIV context. Empiric data from more than 100 HIV
treatment programs in Africa, Asia and Latin America
were used to determine the best performing universal def-
inition of LFU, and recommend use of ≥180 days since last
clinic visit as standard definition of LFU in HIV programs
[23]. For the purpose of this study, LFU was therefore de-
fined as individuals who were ≥180 days late since their last
clinic visit.
To facilitate survival analysis, we assumed that individ-
uals who initiated ART but never returned over the
2 years follow up period contributed one day of follow
up each. Individuals remaining in care were censored at
Figure 1 Flow diagram illustrating the eligibility of the HIV patient
population to study attrition in a rural HIV clinic in Coastal Kenya
between 2004 and 2010 (N = 7,470).
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either reported dead, LFU or had transferred care to other
health facilities were censored at their last clinic visit date.
Data analysis
A distribution of baseline characteristics of the study
participants by gender was done. Continuous data were
presented using medians and Interquartile ranges (IQR).
Categorical data were presented using frequencies and
percentages. Participants with missing data were coded
and presented as separate categories within variables.
Kaplan Meier (KM) survival curves were used to describe
the probability of attrition from ART care over follow up
time. Weibull baseline hazard regression analyses were
used to model the incidence of attrition over time. Univari-
able Weibull regression analyses were done to assess
for individual predictors of time to attrition. To ensure
representativeness of the study population, and to avoid
potentially excluding a biased population from the ana-
lyses, categories with >20% missing observations within
variables were also included in the regression analyses.
Crude Hazard Ratios (cHR), 95% CI and Likelihood
Ratio Test (LRT) p-values were presented.
Multivariable Weibull regression analyses were done
to determine independent predictors of time to attrition.
A forward stepwise model building approach was used.
Predictors with a LRT p-value of <0.05 from the univari-
able analyses were carried forward to the multivariable
analyses. Based on literature and their potential for sig-
nificance, gender, age, BMI and CD4 T-cell count were
considered a-priori predictors of time to attrition and
were also included in the multivariable analyses. Adjusted
Hazard ratios (aHR), 95% CI and LRT p-values were
presented.
All data analyses were carried out using Stata statistics
package (Stata 12.0, StataCorp, College Station, Texas, USA).
Ethical considerations
These analyses were based on data routinely collected
for a surveillance project on antiretroviral drug resistance
and treatment outcomes in Kilifi, Kenya. Science and
Ethics approvals were granted by the Scientific Steering
Committee and the National Ethics and Review Com-
mittee of the Kenya Medical Research Institute respect-
ively (SSC No. 1341).
Results
Cohort characteristics
Overall, 7,470 individuals were registered for HIV care
in the clinic between 2004 and 2010. The study cohort
population comprised 928 adults initiating ART between
January 2008 and December 2010 (Figure 1). Of these,
666 (71.8%) were women and 433 (46.7%) did not have a
baseline CD4 T-cell count (Table 1).Incidence of attrition
Of the 928 adults initiated ART and followed up for
2 years, 523 (56.4%) were retained and on active follow
up while 97 (10.5%) were formally transferred to other
health facilities of their choice for follow up ART care.
Fifty-five (5.9%) were reported dead and 253 (27.3%) were
LFU.
Overall, the 928 adults on ART contributed a total of
1,336 person years of observation (pyo). Of these, 308
(33.2% [95% CI, 30.2 – 36.3]) underwent attrition at an
incident rate of 23.1 (95% CI, 20.6 – 25.8)/100 pyo
(Figure 2). The number of individuals who had
undergone attrition by 6 and 12 months were 171
(18.4% [95% CI, 16.0 – 21.1]) and 209 (23.2% [95% CI,
19.9 – 25.3]) respectively. Sixty-seven individuals (7.2%
[95% CI, 5.6 – 9.1]) started treatment but did not return
for follow up ART care.
Table 1 Distribution of baseline characteristics in HIV-infected adults initiated antiretroviral therapy in a rural HIV
clinic in Coastal Kenya (N = 928)
Characteristics Categories Male (N = 262) Female (N = 666) Total(N = 928)
*Age (years) Median 39.1 34.8 36.2
[IQR] [34.7 – 45.5] [29.1 – 41.1] [30.2 – 42.5]
Age group (years) 15 – 24 7 [2.7] 88 [13.2] 249 95 [10.2]
25 – 34 66 [25.2] [37.4] 315 [33.9]
35 – 44 120 [45.8] 210 [31.5] 330 [35.6]
≥ 45 69 [26.3] 119 [17.9] 188 [20.3]
Marital status Single 19 [7.3] 50 [7.5] 69 [7.4]
Married, Monogamous 169 [64.5] 229 [34.4] 398 [42.9]
Married, Polygamous 30 [11.5] 126 [18.9] 156 [16.8]
Separated/Divorced/Widowed 44 [16.8] 259 [38.9] 303 [32.7]
Missing 0 [0.0] 2 [0.3] 2 [0.2]
Religion Christian 168 [64.1] 399 [59.9] 567 [61.1]
Muslim 45 [17.2] 114 [17.1] 159 [17.1]
Others 46 [17.6] 146 [21.9] 192 [20.7]
Missing 3 [1.2] 7 [1.1] 10 [1.1]
Education No formal education 30 [11.5] 285 [42.8] 315 [33.9]
Primary education 139 [53.1] 281 [42.2] 420 [45.3]
Secondary/Higher education 90 [34.4] 94 [14.1] 184 [19.8]
Missing 3 [1.2] 6 [0.9] 9 [1.0]
*Distance from hospital (km) Median 7.8 7.8 7.8
[IQR] [2.2 – 16.8] [2.2 – 17.7] [2.2 – 17.7]
Distance from hospital (km) 0 – 5 96 [36.6] 251 [37.7] 347 [37.4]
5 – 10 54 [20.6] 148 [22.2] 202 [21.8]
≥ 10 75 [28.6] 189 [28.4] 264 [28.5]
Missing 37 [14.1] 78 [11.7] 115 [12.4]
*Pre-ART duration (months) Median 4.7 6.6 6.3
[IQR] [1.6 – 16.7] [2.2 – 23.3] [1.9 – 21.4]
Pre-ART duration groups (months) 0 – 12 184 [70.2] 420 [63.1] 604 [65.1]
12 – 36 58 [22.1] 166 [24.9] 224 [24.1]
≥ 36 20 [7.6] 80 [12.0] 100 [10.8]
Baseline WHO clinical staging Stage I/II 118 [45.0] 393 [59.0] 511 [55.1]
Stage III/IV 120 [45.8] 238 [35.7] 358 [38.6]
Missing 24 [9.2] 35 [5.3] 59 [6.4]
*Baseline BMI (Kg/m2) Median 19.1 19.3 19.3
[IQR] [17.3 – 21.3] [17.3 – 21.9] [17.3 – 21.6]
Baseline BMI groups (Kg/m2) <16.0 30 [11.5] 67 [10.1] 97 [10.5]
16.0 – 18.5 62 [23.7] 172 [25.8] 234 [25.2]
>18.5 127 [48.5] 347 [52.1] 474 [51.1]
Missing 43 [16.4] 80 [12.0] 123 [13.3]
*Baseline CD4 (cells/ul) Median 135 166 157
[IQR] [30–213] [53–240] [46–234]
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Table 1 Distribution of baseline characteristics in HIV-infected adults initiated antiretroviral therapy in a rural HIV
clinic in Coastal Kenya (N = 928) (Continued)
Baseline CD4 groups (cells/uL) 0 – 100 64 [24.4] 121 [18.2] 185 [19.9]
100 – 350 68 [25.9] 197 [29.6] 265 [28.6]
>350 11 [4.2] 34 [5.1] 45 [4.9]
Missing 119 [45.4] 314 [47.2] 433 [46.7]
ART (Antiretroviral therapy), BMI (Body Mass Index), IQR (Interquartile range), WHO (World Health Organization).
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In multivariable analyses, gender, baseline CD4 T-cell
count and age group independently predicted attrition
from ART care (Table 2).
Men had 50% higher rate of attrition from ART care
compared to women (aHR [95% CI]: 1.5 [1.1 – 2.0],
p = 0.014). The difference in the incidence of ART
attrition between men and women was most evident
within the first year of ART, with no substantial change
thereafter (Figure 3(a)).
Participants with a CD4 T-cell count of 100–350 cells/ul
had half the rate of attrition compared to those with a
CD4 T-cell count of <100 cells/ul (0.5 [0.3 – 0.7],
p = 0.002). The difference in the incidence of attrition
between these two groups was highest within the first year
of ART initiation, with no substantial change in the rate of
attrition thereafter. Interestingly, there was no evidence for
a difference in the overall attrition rates between individuals
with a CD4 T-cell count of >350 cells/ul when compared
to those with a CD4 T-cell count of <100 cells/ul (aHR
[95% CI]: 0.8 [0.4 – 1.5]). In addition, participants with a
missing baseline CD4 T-cell count had about the sameFigure 2 Kaplan Meier survival estimates for attrition among individuals w
Kenya (N = 928).incidence of attrition from ART care, compared to those
with CD4 T-cell counts of <100 cells/ul. (Figure 3(c)).
After adjusting for gender, baseline WHO staging, base-
line BMI and baseline CD4 T-cell count, age independ-
ently predicted attrition from ART care. Individuals aged
15–24 years were more than two-fold more likely to
undergo attrition, compared to those aged ≥45 years (2.2
[1.3 – 3.7], p = 0.034). Contrary to gender and CD4 T-cell
count, the variation in attrition by age groups was most
evident after one year on ART, with no substantial differ-
ence in the attrition rates within the first year of treatment
(Figure 3(b)).
Gender, age and baseline CD4 T-cell count positively
confounded the effect of baseline WHO staging and
baseline BMI on ART attrition. After adjusting for these,
the effect of participants with a baseline WHO clinical
stage III/IV on ART attrition was attenuated to the null,
when compared to those with baseline WHO clinical
stage I/II (1.1 [0.8 – 1.5], p = 0.527). Similarly, the effect
of baseline BMI <16.0 was also attenuated to the null,
when compared to those with a baseline BMI of ≥18.5
(1.6 [1.0 – 2.4], p = 0.110).ho initiated antiretroviral therapy in a rural HIV clinic in Coastal
Table 2 Weibull univariable and multivariable analysis for predictors of time to attrition (lost to follow up and death)
among adults initiated antiretroviral care in a rural HIV clinic in Coastal Kenya (N = 928)
Univariable Regression Multivariable regression
(n = 761)
Characteristics Categories Attrition, n = 308
(n/100 pyo [rate])
Crude HR 95% CI LRT
p-value
Adjusted HR 95% CI LRT
p-value
Gender Female 208/9.92 [21.0] 1.0 (Reference) 1.0 (Reference)
Male 100/3.44 [29.1] 1.3 1.1 – 1.7 0.018 1.5 1.1 – 2.0 0.014
Age group (years) 15 – 24 38/1.24 [30.6] 1.5 1.0 – 2.2 2.2 1.3 – 3.7
25 – 34 103/4.59 [22.4] 1.1 0.8 – 1.6 1.4 0.9 – 2.1
35 – 44 112/4.74 [23.6] 1.2 0.9 – 1.6 1.3 0.9 – 2.0
≥45 55/2.78 [19.8] 1.0 (Reference) 0.318 1.0 (Reference) 0.034
*Marital status Single 28/0.97 [29.0] 1.0 (Reference)
Married, Monogamous 128/5.69 [22.5] 0.8 0.5 – 1.2
Married, Polygamous 48/2.39 [20.1] 0.7 0.4 – 1.1
Separated/Divorced/Widowed 103/4.29 [24.0] 0.8 0.5 – 1.3 0.548
*Religion Christian 188/8.02 [23.4] 1.0 (Reference)
Muslim 55/2.37 [23.3] 1.0 0.7 – 1.4
Others 60/2.83 [21.2] 0.9 0.7 – 1.2 0.859
*Education No formal education 104/4.59 [22.6] 1.0 (Reference)
Primary education 144/6.02 [23.9] 1.0 0.8 – 1.3
Secondary/Higher education 54/2.61 [20.7] 0.9 0.6 – 1.2 0.608
*Distance from
hospital (km)
0 – 5 119/5.0 [23.7] 1.0 (Reference)
5 – 10 57/3.2 [18.1] 0.8 0.6 – 1.1
≥10 82/3.9 [21.2] 0.9 0.7 – 1.2 0.270
Pre-ART duration
(months)
<12 207/8.6 [24.0] 1.0 (Reference)
12 – 36 68/3.2 [20.9] 0.9 0.7 – 1.2
≥36 33/1.5 [22.1] 0.9 0.6 – 1.4 0.663
*Baseline WHO clinical
staging
Stage I/II 141/8.13 [17.4] 1.0 (Reference) 1.0
Stage III/IV 124/5.05 [24.5] 1.4 1.1 – 1.8 0.009 1.1 0.8 – 1.5 0.527
*Baseline BMI (Kg/m2) <16.0 41/1.12 [36.7] 2.1 1.5 – 2.9 1.6 1.0 – 2.4
16.0 – 18.5 72/3.53 [20.4] 1.2 0.9 – 1.6 1.0 0.7 – 1.4
≥18.5 128/7.58 [16.9] 1.0 (Reference) <0.001 1.0 (Reference) 0.110
Baseline CD4 (cells/uL) 0 – 100 70/2.50 [28.0] 1.0 (Reference) 1.0 (Reference)
100 – 350 54/4.46 [12.1] 0.5 0.3 – 0.7 0.5 0.3 – 0.7
≥350 15/0.66 [22.6] 0.8 0.5 – 1.4 0.8 0.4 – 1.5
Missing 169/5.74 [29.4] 1.1 0.8 – 1.4 <0.001 0.7 0.5 – 1.0 0.002
ART (Antiretroviral therapy), BMI (Body Mass Index), LRT (Likelihood Ratio Test), pyo (person years of observation), WHO (World Health Organization).
*Participants excluded from Weibull regression analysis (n = 167) due to missing marital status (n = 2), religion (n = 10), education status (n = 9), distance from
hospital (n = 115), baseline WHO clinical staging (n = 59) and/or BMI (n = 123) data.
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Data from a rural HIV clinic in Coastal Kenya suggest
that a third of adults who initiated ART were either LFU
or reported dead after 2 years, with more than a half of
the attrition occurring within six months of ART initi-
ation. These findings indicate higher levels of attrition in
this setting than suggested by data from systematic re-
views of ART programs across sSA reporting around 25%
attrition rates after 2 years [5,7]. However, the findings areconsistent with data from other parts of Kenya reporting
attrition rates of about 20% at six to twelve months and
35% at 2 years [16,18]. Collectively, these findings there-
fore suggest that attrition remains a major challenge for
ART programs in Kenya.
While literature attributes more than 40% of attrition
to death [5,7], this was only 18% in our setting. Rather
than suggesting a low mortality rate, we posit that this
is an underestimate resulting from passive surveillance
Figure 3 Kaplan Meier survival estimates for attrition among adults initiated ART in a rural HIV clinic in Coastal Kenya by gender (a), age groups
(b), and CD4 T-lymphocytes count groups (c).
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of those LFU are actually dead. Indeed, studies tracing
HIV-infected LFU individuals report more than 40%
deaths among those successfully traced [24,25], with
the risk of mortality being highest within the first year
of LFU [26,27].
At ART initiation, men were older, in more advanced
stages of HIV/AIDS and had higher rates of attrition,
especially within the first year of treatment. Participants
with severe immunosuppression at ART initiation also
had higher rates of attrition, especially within the first year
of ART. These findings are consistent with data from
other studies [11,12,28-30] and are suggestive of late HIV
diagnosis and ART initiation, more so in men. Unlike
men, women have more opportunities of being diagnosed
with HIV infection and identified for ART initiation
earlier on through hospital-based initiatives, including
prevention of mother to child transmission interventions.
This therefore underscores the importance of increasing
efforts towards early identification of HIV infection in
men through testing and linkage to care initiatives. In
addition pre-ART lab monitoring and support systems
should be strengthened for timely ART initiation [22].
Biomedical interventions, including more potent effica-
cious regimen, are also needed to mitigate early ART at-
trition through mortality in these high-risk individuals.
Younger participants had higher rates of attrition com-
pared to the older participants. This finding has also been
reported elsewhere [8,11,30]. Of interest, however, is that
the difference observed in attrition rates by age group was
only evident in the second year of treatment. We postulate
that this may have arisen as a result of psychosocial
challenges including stigma, discrimination and lack of
disclosure, among the younger participants [31]. Indeed,
early HIV status disclosure in adolescents on ART has been
shown to improve retention [32]. Therefore, the period
immediately after ART initiation offers a window of op-
portunity to address psychosocial challenges, including
facilitating disclosure and peer support, towards mitigat-
ing later attrition from ART care among the youth and
young adults.
Almost half the participants did not have a baseline
CD4 T-cell count and were likely initiated ART because
of advanced disease based on WHO clinical staging. This
is not uncommon in resource-constrained settings and
is a reflection of programmatic challenges resulting from
scale up of ART, which has not always been done in
tandem with the necessary lab monitoring and support
systems. In addition, participants with a missing CD4
T-cell count had equally high rates of attrition as those
with CD4 T-cell count of less than 100 cells/uL, sug-
gesting that missing CD4 T-cell count at ART initi-
ation is a good proxy for severe immunosuppression,
which is associated with early mortality after treatmentinitiation in developing settings. In this context, there-
fore, it is possible that more than a half of those start-
ing ART had severe immunosuppression.
Findings from this study should be interpreted in light
of several limitations. Firstly, the passive nature of our
surveillance means that the possibility of individuals
who were determined LFU actually being on active care
in another health facility (self-referrals) cannot be ruled
out. This may have resulted in an overestimation of attri-
tion in our analyses. However, emphasis was put on for-
mal referrals, accompanied with a formal transfer form in
all health facilities offering HIV services in this setting. All
formal referrals were documented and considered in the
analyses.
Secondly, and despite the passive surveillance, the pres-
ence of a research team in the clinic may have resulted to
an improved quality of care, albeit in a routine program-
matic context. This may have resulted in an underestima-
tion of attrition, suggesting that attrition may actually be
higher in other routine non-research facilities in rural
settings in Kenya.
Conclusions
Whilst ART scale up and treatment coverage has been
impressive overall, high attrition remains a major chal-
lenge for the success of ART program in our setting. Poor
pre-ART lab monitoring systems, late ART initiation, ad-
vanced HIV disease at time of ART initiation and weak
support systems after treatment initiation may contribute
to the high attrition rates.
Interventions aimed at identifying HIV-infected indi-
viduals and effective linkages to care, especially targeting
men, coupled with strengthened periodic pre-ART lab
monitoring are needed to improve timely ART initiation. In
the immediate short term after ART initiation, biomedical
interventions including more potent efficacious regimens
should be considered to mitigate early attrition through
mortality in the most immunocompromised individuals. In
the long term, psychosocial support systems aimed at
addressing stigma and facilitating disclosure, especially
among the youth and young adults, are needed to offset
late attrition.
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